Business Wire

FOOTPRINT-CAFÉS

21.4.2016 08:01:21 CEST | Business Wire | Press release

Share
Footprint Cafés Launches with $150,000 personal donation from Queens Award Enterprise champion Dr. Darrin M. Disley

Footprint Cafés, a new chain of sustainable enterprise cafés that will re-invest 100% of net profits into local communities has launched today. The brainchild of Georgina Hemmingway, a graduate of the Judge Business School at the University of Cambridge, Footprint Cafés has also attracted the personal endorsement and financial support of Horizon Discovery Group plc CEO, angel investor and enterprise champion, Dr. Darrin M. Disley who was honoured in the Queen’s Birthday Honours today with a Queen’s Award for Enterprise Promotion.

Footprint Cafés aims to establish itself in every corner of the world, becoming the brand for ethically-motivated tourists, giving them an authentic local experience combined with world class standards. Over the past two year Georgina has already proved the business model works with the success of New Leaf Book café in Siem Reap, Cambodia and is now expanding the concept to the cultural city of Battambang, Cambodia. Darrin Disley, who has become a trustee of the charity, has pledged an initial $150,000 cornerstone donation to a fundraising campaign that aims to raise $1 million by 2017.

Dr. Darrin M. Disley, winner of the Queen’s Award for Enterprise Promotion, commented, “I am delighted to be supporting such a uniquely pure and socially impactful project. Georgina’s idea for Footprint Cafés originated at the Judge Business School and it is fantastic to have been part of her journey and see this come to fruition today.

“Ethical entrepreneurship is at the heart of everything I do and is also a quality which is essential for the development of any successful and sustainable growth business. I am grateful not only to be receiving recognition for the work that I have done, but also to be able support Footprint Cafés mission of addressing global illiteracy, gender inequality and local community development, one fantastic Enterprise Café at a time.”

Footprint Cafés has also launched today a second hand book donation drive. Footprint Cafés will send your donated books to Cambodia, donating any children’s books to rural schools and selling all fiction books in their cafes as holiday reads for tourists. All money raised from book sales in the cafes will be given to the local community as grants for educational projects.

Georgina Hemmingway, Founder of Footprint Cafés, added: “Tourism is one of the fastest growing sectors in the world, and it also represents a significant opportunity to connect and empower local communities. At the moment that opportunity is often wasted with profits being drained off-shore to wealthy owners. Footprint Cafes will connect the global to the local by harnessing the spending power of tourism as a force for local change and empowerment one amazing café at a time.”

-Ends-

About the book drive

Footprint Cafes needs previously loved fiction and children’s books. Individuals are encouraged to write messages inside the books to the unknown Footprint customer. Individuals who would like to donate to the drive are asked to write to Footprint cafes directly to organise collection.

Contact info@footprintcafes.org for details on how to donate your books.

About Footprint Cafés – www.footprintcafes.org

Footprint Cafés is a triple-lock social enterprise that is undertaking an audacious but achievable mission of building a chain of sustainable Enterprise Cafés that break down barriers to education and deliver impacting change to local communities.

Founded by Georgina Hemmingway the enterprise builds on the success of over the past three years New Leaf Book café in Siem Reap, Cambodia which now employs 17 staff and has generated and donated its profits to eight local organisations tackling illiteracy, gender inequality and community development

The expansion of the model into the cultural city of Battambang, Cambodia supported by the first phase of a $1 million fund-raising drive has already begun with further plans to expand through Indochina and beyond,

About Dr. Darrin M. Disley’s Queens Award

Dr. Darrin M. Disley is the co-founder and Chief Executive Officer of Horizon Discovery Group plc, a successful UK listed life science company based in Cambridge. Dr Disley has made a major contribution to raising the profile of life sciences both in Cambridge and beyond.

As part of his endeavours, he has concentrated on a voluntary programme to raise the profile of entrepreneurship and its connection with life sciences. He has given many hours of time to aid young entrepreneurs through mentoring and speaking engagements. In the past four years, over 100 young entrepreneurs have benefited from his advice, time and financial support and almost a dozen businesses have been launched, raising over ten million pounds in capital. He remains an advisor to many of them.

Darrin also provides assistance to several social enterprises, students from underprivileged backgrounds and advises and assists two universities along with Cambridge University Entrepreneurs.

Contact:

For Media Enquiries
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson, Matthew Neal
Fennell@consilium-comms.com
Tel: +44 (0) 203 709 5700

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye